Prognosis of body mass index and chemotherapy dose capping in acute myeloid leukaemia

Leukemia Research

Volumn 38, Issue 12, 2014, Pages 1425-1429

  Kempf, Emmanuelle ^a,b   Hirsch, Pierre ^a,b,c   Labopin, Myriam ^a,c   Viguié, Frank ^a   Isnard, Françoise ^a,b   Tang, Ruoping ^a,b,c   Marzac, Christophe ^a   Marie, Jean Pierre ^a,b   Mohty, Mohamad ^a,b,c   Legrand, Ollivier ^a,b,c  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c CENTRE DE RECHERCHE SAINT ANTOINE   (France)

Author keywords

AML; BMI; Chemotherapy dose capping; Obesity; Prognosis

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYTARABINE; ETOPOSIDE; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BODY MASS; BODY SURFACE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CHEMOTHERAPY DOSE CAPPING; CHROMOSOME ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOSE CALCULATION; FEMALE; FLT3 ITD GENE; GENE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; OVERALL SURVIVAL; UNDERWEIGHT; CLINICAL TRIAL; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MULTICENTER STUDY; PROGNOSIS; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY MASS INDEX; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROGNOSIS;

EID: 84915804948     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.09.013     Document Type: Article

References (22)

1. Larsson S.C., Wolk A. Overweight and obesity and incidence of leukemia: a meta-analysis of cohort studies. Int J Cancer 2007, 122(November (6)):1418-1421.
2. Brunner A.M., Sadrzadeh H., Feng Y., Drapkin B.J., Ballen K.K., Attar E.C., et al. Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia. Am J Hematol 2013, 88(August (8)):642-646.
3. Medeiros B.C., Othus M., Estey E.H., Fang M., Appelbaum F.R. Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia. Haematologica 2012, 97(September (9)):1401-1404.
4. Calle E.E., Rodriguez C., Walker-Thurmond K., Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S adults. N Engl J Med 2003, 348(April (17)):1625-1638.
5. Lee H.J., Licht A.S., Hyland A.J., Ford L.A., Sait S.N., Block A.W. Is obesity a prognostic factor for acute myeloid leukemia outcome?. Ann Hematol 2012, 91(March (3)):359-365.
6. Lin A., Othus M., McQuary A., Chi M., Estey E. Influence of obesity on efficacy and toxicity of induction chemotherapy in patients with newly diagnosed acute myeloid leukemia. Leuk Lymphoma 2013, 54(March (3)):541-546.
7. Pinkel D. The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res 1958, 18(August (7)):853-856.
8. Jan H.B., Edward C., Salvatore J.S. Body-surface area-based chemotherapy dosing: appropriate in the 21st Century?. J Clin Oncol 2012, 30(January (31)):3896-3897.
9. Krogh-Madsen M., Bender B., Jensen M.K., Nielsen O.J., Friberg L.E., Honoré P.H. Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia. Cancer Chemother Pharmacol 2012, 69(May (5)):1155-1163.
10. Lopes-Serrao M.D., Ussery S.M., Hall R.G., Shah S.R. Evaluation of chemotherapy-induced severe myelosuppression incidence in obese patients with capped dosing. J Oncol Pract 2011, 7(1):13-17.
11. Lyman G.H. Commentary: chemotherapy dosing in obese patients with cancer - the need for evidence-based clinical practice guidelines. J Oncol Pract 2011, 7(January (1)):17-18.
12. Griggs J.J., Mangu P.B., Anderson H., Balaban E.P., Dignam J.J., Hryniuk W.M., et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2012, 30(January (13)):1553-1561.
13. Hourdequin K.C., Schpero W.L., McKenna D.R., Piazik B.L., Larson R.J. Toxic effect of chemotherapy dosing using actual body weight in obese versus normal-weight patients: a systematic review and meta-analysis. Ann Oncol 2013, 24(December (12)):2952-2962.
14. Wenzell C.M., Gallagher E.M., Earl M., Yeh J.Y., Kusick K.N., Advani A.S., et al. Outcomes in obese and overweight acute myeloid leukemia patients receiving chemotherapy dosed according to actual body weight. Am J Hematol 2013, 88(Oct):906-909.
15. Amadori S., Suciu S., Jehn U., Stasi R., Thomas X., Marie J.P., et al. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood 2005, 106(January 1):27-34.
16. Mandelli F., Vignetti M., Suciu S., Stasi R., Petti M.C., Meloni G., et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA groups study AML-10. J Clin Oncol 2009, 27(October (32)):5397-5403.
17. Willemze R., Suciu S., Meloni G., Labar B., Marie J.P., Halkes C.J., et al. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. J Clin Oncol 2014, 32(January (3)):219-228.
18. Grimwade D., Walker H., Oliver F., Wheatley K., Harrison C., Harrison G., et al. The Importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The medical research council adult and children's leukaemia working parties. Blood 1998, 92(October (7)):2322-2333.
19. Hirsch P., Tang R., Marzac C., Perrot J.Y., Fava F., Bernard C., et al. Prognostic impact of high ABC transporter activity in 111 adult acute myeloid leukemia patients with normal cytogenetics when compared to FLT3, NPM1, CEBPA and BAALC. Haematologica 2012, 97(February (2)):241-245.
20. WHO Technical Report Series 854 Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee 1995, World Health Organization, Geneva.
21. Cheson B.D., Bennett J.M., Kopecky K.J., Büchner T., Willman C.L., Estey E.H., et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in acute myeloid leukemia. J Clin Oncol 2003, 21(December (24)):4642-4649.
22. Fernandez H.F., Sun Z., Yao X., Litzow M.R., Luger S.M., Paietta E.M., et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009, 361(September (13)):1249-1259.